HUTCHMED (CHINA) LIMIT

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

08 11 2023 19:11:18 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

16 10 2023 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

29 9 2023 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

12 9 2023 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

11 9 2023 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

28 8 2023 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

20 8 2023 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

31 7 2023 07:41:53 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

19 7 2023 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Changes to Board of Directors and Technical Committee 

13 7 2023 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

09 7 2023 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Half-Year Financial Results

26 6 2023 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

15 6 2023 20:30:00 提供 Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

15 6 2023 10:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

09 6 2023 05:30:00 提供 Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

25 5 2023 19:00:54 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

25 5 2023 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Board of Directors and Board Committee Membership

12 5 2023 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

10 5 2023 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

17 4 2023 20:00:00 提供 Nasdaq GlobeNewswire